Bottom line
RYCFX vs SHPAX: the short answer
RYCFX (Biotechnology Fund) and SHPAX (Health & Biotechnology Portfolio) are both mutual funds.
But RYCFX is far broader, holding 74 positions to 29 for SHPAX, so beyond the top names it adds exposure SHPAX doesn't have.
RYCFX is cheaper at 2.38% vs 3% — a difference of $62 a year per $10,000 invested.
Over five years, SHPAX returned +3.1% a year vs +3.0% for RYCFX (reporting dates differ).
SHPAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
RYCFX vs SHPAX side by side
| RYCFX | SHPAX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Guggenheim | Saratoga Advantage |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 2.38% | 3% |
| Annual cost per $10k | $238 | $300 |
| 10-yr cost on $10k (prospectus) | $2,763 | $3,702 |
| Max front load | 0% | 5.75% |
| 12b-1 fee | 1% | — |
| 1-yr return | +28.4% | −5.5% |
| 5-yr return (annualized) | +3.0% | +3.1% |
| 10-yr return (annualized) | +4.8% | +4.1% |
| Best quarter | +28.0% | +15.0% |
| Worst quarter | −22.7% | −13.0% |
| Net assets (fund) | $136.8M | $10.5M |
| Number of holdings | 74 | 29 |
| Portfolio turnover | 75% | 22% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | RYCFX | SHPAX | Difference |
|---|---|---|---|
| 2024 | −1.7% | +0.3% | −2.0% |
| 2023 | +5.0% | −0.4% | +5.4% |
| 2022 | −13.9% | +2.0% | −16.0% |
| 2021 | +0.8% | +16.7% | −15.9% |
| 2020 | +20.9% | +3.6% | +17.3% |
| 2019 | +23.8% | +16.2% | +7.6% |
| 2018 | −9.9% | −5.5% | −4.4% |
| 2017 | +28.4% | +12.0% | +16.5% |
| 2016 | −20.3% | −2.0% | −18.3% |
Source: Fund prospectus bar charts
Holdings overlap
6 of RYCFX's top 25 holdings also appear in SHPAX's top 25.
| Holding | RYCFX | SHPAX |
|---|---|---|
| Amgen Inc | 5.05% | 5.04% |
| Gilead Sciences Inc | 4.49% | 3.94% |
| Vertex Pharmaceuticals Inc | 4.32% | 3.36% |
| Regeneron Pharmaceuticals Inc | 2.93% | 3.93% |
| United Therapeutics Corp | 1.72% | 6.17% |
| Incyte Corp | 1.62% | 2.89% |
Source: SEC Form N-PORT
RYCFX top 10
- Abbvie Inc — 8.17%
- Amgen Inc — 5.05%
- Gilead Sciences Inc — 4.49%
- Vertex Pharmaceuticals Inc — 4.32%
- Regeneron Pharmaceuticals Inc — 2.93%
- Revolution Medicines Inc — 2.48%
- Alnylam Pharmaceuticals Inc — 2.36%
- Beone Medicines Ltd — 2.17%
- Moderna Inc — 2.15%
- Biogen Inc — 2.13%
SHPAX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
FAQ
What is the difference between RYCFX and SHPAX?
Which is cheaper, RYCFX or SHPAX?
Should I own both RYCFX and SHPAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.